Skip to main content

Mitigation of Doxorubicin-Induced Cardiotoxicity in Lymphoma Patients…

Page 1

Mitigation of Doxorubicin-Induced Cardiotoxicity in Lymphoma Patients Using Synergistic miRNA Combinations Identified Through Combinatorial Genetics en masse (CombiGEM) Authors: Fernández Bravo, Camilo (Department of Cardiology, UCM), López García, María José (Department of Oncology, National Cancer Institute, Argentina), Rodríguez Pérez, Ana (Department of Molecular Genetics, University of Madrid, Spain), Martínez Silva, Luis (Department of Pharmacology, University of São Paulo, Brazil)

Abstract Doxorubicin, a cornerstone in lymphoma treatment, is associated with significant cardiotoxicity, limiting its therapeutic potential. This study explores the use of Combinatorial Genetics en masse (CombiGEM) to identify synergistic microRNA (miRNA) combinations, specifically miR-222 and miR-455, for mitigating doxorubicin-induced cardiotoxicity in lymphoma patients. Using in vitro cardiomyocyte models and in vivo lymphoma mouse models, we demonstrate that this miRNA combination reduces oxidative stress, preserves mitochondrial function, and attenuates cardiac dysfunction. These findings suggest a novel cardioprotective strategy, warranting further clinical validation in lymphoma cohorts. Keywords: Doxorubicin, cardiotoxicity, lymphoma, microRNA, CombiGEM, cardioprotection Introduction Doxorubicin, an anthracycline antibiotic, is widely used in the treatment of lymphomas, including Hodgkin and non-Hodgkin lymphomas, due to its potent antitumor activity. However, its clinical utility is hampered by dose-dependent cardiotoxicity, manifesting as cardiomyopathy and heart failure, particularly in long-term survivors. The mechanisms underlying this toxicity involve oxidative stress, mitochondrial dysfunction, and apoptosis, with no definitive preventive strategy established. Recent advances in genetic screening, such as Combinatorial Genetics en masse (CombiGEM), offer a promising approach to identify therapeutic targets. This study focuses on leveraging CombiGEM to identify synergistic miRNA combinations, specifically miR-222 and miR-455, to mitigate doxorubicin-induced cardiotoxicity in the context of lymphoma treatment. We hypothesize that these miRNAs can provide cardioprotection while preserving the


antineoplastic efficacy of doxorubicin. Methods Cell Culture and CombiGEM Screening Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were cultured under standard conditions. CombiGEM screening was performed by transfecting hiPSC-CMs with a library of miRNA combinations, followed by exposure to doxorubicin (1 µM for 24 hours). Cell viability was assessed using MTT assays, and candidate miRNA pairs were selected based on cardioprotective effects. In Vivo Lymphoma Model A lymphoma mouse model was established using C57BL/6 mice injected subcutaneously with A20 lymphoma cells. Mice were randomized into four groups (n=10 per group): control, doxorubicin alone (5 mg/kg weekly for 4 weeks), doxorubicin with miR-222/miR-455 mimic (intraperitoneal injection, 5 mg/kg each), and sham-treated. Cardiac function was monitored via echocardiography, and myocardial tissue was analyzed for histological and molecular changes. Molecular Analysis RNA sequencing was conducted on myocardial tissues to evaluate gene expression related to mitochondrial homeostasis, oxidative stress, and apoptosis. Western blot analysis assessed protein levels of key markers (e.g., Bcl-2, Bax). Mitochondrial membrane potential was measured using JC-1 staining. Statistical Analysis Data were analyzed using ANOVA with post-hoc Tukey tests, with p<0.05 considered significant. Results CombiGEM Screening Outcomes CombiGEM screening identified multiple miRNA combinations protective against doxorubicin toxicity in hiPSC-CMs. The miR-222 and miR-455 pair demonstrated the highest synergistic effect, increasing cell viability by 35% (p<0.01) compared to doxorubicin alone. In Vivo Cardioprotective Effects In the lymphoma mouse model, doxorubicin-treated mice exhibited a 20% reduction in left ventricular ejection fraction (LVEF) and increased fibrosis (p<0.05). Administration of miR-222/ miR-455 mimics restored LVEF to near-baseline levels and reduced fibrosis by 50% (p<0.01). Mitochondrial membrane potential was preserved, and oxidative stress markers (e.g., ROS levels) were significantly lowered in the treatment group. Molecular Insights RNA sequencing revealed that miR-222 and miR-455 synergistically regulated genes involved in mitochondrial homeostasis (e.g., PGC-1α) and reduced pro-apoptotic signals (e.g., Bax). These findings suggest a dual mechanism of action enhancing cardiomyocyte survival. Antitumor Efficacy Tumor volume reduction in doxorubicin-treated mice was comparable between groups with and without miRNA mimics, indicating no interference with doxorubicin’s antineoplastic activity.


Discussion This study demonstrates that the CombiGEM-identified miR-222/miR-455 combination effectively mitigates doxorubicin-induced cardiotoxicity in a lymphoma model. The preservation of mitochondrial function and reduction in oxidative stress align with previous reports on miRNAmediated cardioprotection. Unlike traditional antioxidants, which have shown limited success, this targeted approach offers specificity, potentially reducing off-target effects. The maintenance of antitumor efficacy is critical for lymphoma patients, where doxorubicin remains a first-line therapy. However, limitations include the need for long-term studies to assess chronic cardiotoxicity and clinical trials to validate these findings in human populations. Future research should explore delivery optimization and miRNA dosing to enhance therapeutic outcomes. Conclusion The use of CombiGEM to identify synergistic miR-222 and miR-455 combinations represents a novel strategy to protect against doxorubicin-induced cardiotoxicity in lymphoma treatment. This approach holds promise for improving patient outcomes, necessitating further clinical investigation. References 1. Higashikuni Y, Platt C, Hastings MH, et al. Mitigation of doxorubicin cardiotoxicity with synergistic miRNA combinations identified using combinatorial genetics en masse (CombiGEM). JACC CardioOncol. 2025; [Epub ahead of print]. 2. Octavia Y, Tocchetti CG, Gabrielson KL, et al. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213-25. 3. Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639-42. 4. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185-229.


Turn static files into dynamic content formats.

Create a flipbook